$8.81
-1.2%Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Weak cash conversion. Significant portion of earnings not converting to cashโreview working capital trends and capital intensity.
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
NEOG โข NASDAQ
| Neogen Corporation Cash Flow Statement | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | May 2009 | May 2008 | May 2007 | May 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-1.1B | -9.4M | -22.9M | 48.3M | 60.9M | 59.5M | 60.2M | 63.1M | 43.8M | 36.6M | 33.5M | 28.2M | 27.2M | 22.5M | 22.8M | 17.5M | 13.9M | 12.1M | 9.1M | 7M | |
125.7M | 121.2M | 90.5M | 24.1M | 21M | 18.4M | 17.6M | 17.1M | 14.7M | 12.2M | 10.6M | 9.2M | 7.4M | 6.2M | 5.3M | 4.4M | 3.9M | 3.5M | 2.8M | 2.4M | |
-57.8M | -27.4M | -19.2M | -4.7M | -640K | 1.6M | 1.2M | -3M | -292K | 1.9M | 496K | -542K | 287K | 1.3M | 2.3M | -200K | 1.6M | 450K | 813K | 485K | |
17.3M | 13.8M | 10.2M | 7.2M | 6.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.1B | 9.8M | 6.7M | -2.4M | 0.0 | 6.5M | 5.5M | 5M | 1.5M | 2.5M | 2M | -1.2M | -198K | 626K | -755K | 1.3M | 1.3M | 1.4M | 1.2M | 912K | |
(26.5M) | (22.3M) | (15.5M) | (17.2M) | (15M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-5.9M | -72.7M | -24.2M | -4.4M | -6.6M | -62K | -20.7M | -13.1M | 563K | -17.8M | -2.9M | -13.9M | -8.1M | -8.4M | -823K | 4.9M | -9.6M | -9.6M | -3.8M | 716K | |
58.2M | 35.3M | 41M | 68M | 81.1M | 85.9M | 63.8M | 69.1M | 60.3M | 35.3M | 43.8M | 21.7M | 26.6M | 22.3M | 28.8M | 28M | 11M | 7.9M | 10.2M | 11.6M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-104.6M | -111.4M | -65.8M | -24.4M | -26.7M | -24.1M | -14.7M | -20.9M | -14.6M | -14.2M | -9.6M | -11.5M | -8.9M | -12.4M | -7.8M | -5.4M | -2.8M | -2.5M | -4.7M | -2.7M | |
(5.1M) | (108K) | (12.5M) | -38.7M | -50.8M | -13.2M | -6.4M | -891K | -34M | -42.5M | -6.6M | -39.3M | -13.3M | -4M | (0.0) | -20.3M | -11.1M | -10.1M | (0.0) | -20.7M | |
(0.0) | (0.0) | -12.5M | -415.9M | -792.7M | -458.3M | -437.3M | -361.4M | -162.8M | -151.6M | -105.9M | -91.7M | -82.8M | -71.6M | -60.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
325K | 82M | 266.8M | 381.8M | 764.6M | 406.7M | 339.2M | 299.8M | 149.2M | 147.2M | 93.7M | 91.2M | 67M | 72.3M | 40.1M | 0.0 | 0.0 | 0.0 | 0.0 | 6.5M | |
-99.2M | -29.3M | (201M) | -97.2M | -105.6M | -88.8M | -119.1M | -83.1M | -62.1M | -61.1M | -28.5M | -51.3M | -38M | -15.8M | -28M | -25.7M | -14M | -12.6M | -4.7M | -23.5M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
2.2M | 2.5M | 1.2M | 7.9M | 34.6M | 29.4M | 13.9M | 23.3M | 21.1M | 12.4M | 8.6M | 14.9M | 9.5M | 5.8M | 10.3M | 5.9M | 2M | 5.1M | 15.4M | 1.5M | |
-321K | -420K | -100M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -10M | 10M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -923K | (0.0) | (0.0) | -29K | |
-3.5M | -118K | -19.3M | -1.1M | -1.1M | 0.0 | 0.0 | 0.0 | 3.9M | 2.9M | 2.5M | 4.8M | 3M | 1.1M | 1.8M | 809K | 564K | 531K | 531K | 328K | |
-1.6M | 1.9M | -118.1M | 6.8M | 33.5M | 29.4M | 13.9M | 23.3M | 25.1M | 15.3M | 11M | 19.6M | 12.5M | 6.9M | 12M | 6.7M | 2.6M | 5.6M | 6M | 11.8M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
942K | -502K | -5.2M | -8.8M | 264K | -1.9M | 21K | -3.4M | -898K | -294K | -984K | 659K | -113K | -167K | 14.2M | -8.6M | 6.8M | -785K | -11.3M | 1.8M | |
-41.6M | 7.4M | 118.8M | -31.1M | 9.3M | 24.6M | -41.4M | 5.5M | 22.3M | -10.8M | 25.4M | -9.4M | 987K | 13.2M | 27M | 321K | 6.4M | 61K | 215K | 1.8M | |
170.6M | 163.2M | 44.5M | 75.6M | 66.3M | 41.7M | 83.1M | 77.6M | 55.3M | 66.1M | 40.7M | 50M | 49M | 35.8M | 8.8M | 8.5M | 2.1M | 2M | 1.8M | 0.0 | |
129M | 170.6M | 163.2M | 44.5M | 75.6M | 66.3M | 41.7M | 83.1M | 77.6M | 55.3M | 66.1M | 40.7M | 50M | 49M | 35.8M | 8.8M | 8.5M | 2.1M | 2M | 1.8M | |
-46.4M | -76.2M | -24.7M | 43.6M | 54.4M | 61.8M | 49.2M | 48.2M | 45.7M | 21.1M | 34.2M | 10.1M | 17.7M | 9.9M | 21M | 22.6M | 8.1M | 5.4M | 5.5M | 8.9M |
NEOG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 09, 2026 | February 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | January 08, 2026 | November 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | October 28, 2025 | August 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 23, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | October 27, 2025 | October 23, 2025 | 2025 |
Continue your NEOG research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.